Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.07
FMS's Cash to Debt is ranked lower than
78% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 0.34 vs. FMS: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
FMS' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.06 Max: N/A
Current: 0.07
Equity to Asset 0.38
FMS's Equity to Asset is ranked lower than
59% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. FMS: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
FMS' s 10-Year Equity to Asset Range
Min: 0.34  Med: 0.41 Max: 0.5
Current: 0.38
0.34
0.5
Interest Coverage 4.55
FMS's Interest Coverage is ranked lower than
62% of the 123 Companies
in the Global Medical Care industry.

( Industry Median: 7.17 vs. FMS: 4.55 )
Ranked among companies with meaningful Interest Coverage only.
FMS' s 10-Year Interest Coverage Range
Min: 1.6  Med: 4.44 Max: 9999.99
Current: 4.55
1.6
9999.99
F-Score: 5
Z-Score: 2.41
M-Score: -2.36
WACC vs ROIC
1.72%
8.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.20
FMS's Operating margin (%) is ranked higher than
73% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 7.02 vs. FMS: 14.20 )
Ranked among companies with meaningful Operating margin (%) only.
FMS' s 10-Year Operating margin (%) Range
Min: 7.8  Med: 14.78 Max: 16.26
Current: 14.2
7.8
16.26
Net-margin (%) 6.43
FMS's Net-margin (%) is ranked higher than
64% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 3.29 vs. FMS: 6.43 )
Ranked among companies with meaningful Net-margin (%) only.
FMS' s 10-Year Net-margin (%) Range
Min: -6.47  Med: 6.53 Max: 8.6
Current: 6.43
-6.47
8.6
ROE (%) 11.28
FMS's ROE (%) is ranked higher than
61% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 8.74 vs. FMS: 11.28 )
Ranked among companies with meaningful ROE (%) only.
FMS' s 10-Year ROE (%) Range
Min: -11.76  Med: 11.78 Max: 14.68
Current: 11.28
-11.76
14.68
ROA (%) 4.35
FMS's ROA (%) is ranked higher than
57% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. FMS: 4.35 )
Ranked among companies with meaningful ROA (%) only.
FMS' s 10-Year ROA (%) Range
Min: -4.47  Med: 4.89 Max: 6.22
Current: 4.35
-4.47
6.22
ROC (Joel Greenblatt) (%) 39.88
FMS's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 15.85 vs. FMS: 39.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FMS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.05  Med: 43.91 Max: 60.99
Current: 39.88
-3.05
60.99
Revenue Growth (3Y)(%) 9.90
FMS's Revenue Growth (3Y)(%) is ranked higher than
61% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. FMS: 9.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FMS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.6  Med: 6.50 Max: 17.2
Current: 9.9
-4.6
17.2
EBITDA Growth (3Y)(%) 6.70
FMS's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. FMS: 6.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FMS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 7.90 Max: 43.1
Current: 6.7
0
43.1
EPS Growth (3Y)(%) 1.60
FMS's EPS Growth (3Y)(%) is ranked lower than
66% of the 113 Companies
in the Global Medical Care industry.

( Industry Median: 9.90 vs. FMS: 1.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FMS' s 10-Year EPS Growth (3Y)(%) Range
Min: -18.1  Med: 13.35 Max: 63.5
Current: 1.6
-18.1
63.5
» FMS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

FMS Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 279,080 sh (+1.95%)
John Keeley 40,000 sh (unchged)
Jim Simons 83,700 sh (-61.20%)
» More
Q4 2014

FMS Guru Trades in Q4 2014

John Keeley 40,000 sh (unchged)
Manning & Napier Advisors, Inc 279,080 sh (unchged)
Jim Simons 21,900 sh (-73.84%)
» More
Q1 2015

FMS Guru Trades in Q1 2015

Jim Simons 61,300 sh (+179.91%)
Manning & Napier Advisors, Inc 312,560 sh (+12.00%)
John Keeley 40,000 sh (unchged)
» More
Q2 2015

FMS Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 312,560 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with FMS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FMCMF67.800.00
FME3.Germany54.200.96
FMSPR0.001.06ADR

Top Ranked Articles about Fresenius Medical Care AG & Co. KGaA

Weekly 52-Week Highs Highlight: FMS, MTB, LO, LEN
According to GuruFocus list of 52-week highs, Fresenius Medical Care AG & Co, M&T Bank Corp, Lorillard Inc, and Lennar Corp have all reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.82
FMS's P/E(ttm) is ranked lower than
51% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. FMS: 26.82 )
Ranked among companies with meaningful P/E(ttm) only.
FMS' s 10-Year P/E(ttm) Range
Min: 13.32  Med: 19.99 Max: 29.39
Current: 26.82
13.32
29.39
Forward P/E 11.51
FMS's Forward P/E is ranked lower than
76% of the 93 Companies
in the Global Medical Care industry.

( Industry Median: 19.31 vs. FMS: 11.51 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.40
FMS's PE(NRI) is ranked lower than
51% of the 140 Companies
in the Global Medical Care industry.

( Industry Median: 27.80 vs. FMS: 28.40 )
Ranked among companies with meaningful PE(NRI) only.
FMS' s 10-Year PE(NRI) Range
Min: 13.2  Med: 19.98 Max: 29.4
Current: 28.4
13.2
29.4
P/B 2.57
FMS's P/B is ranked higher than
51% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 2.74 vs. FMS: 2.57 )
Ranked among companies with meaningful P/B only.
FMS' s 10-Year P/B Range
Min: 1.47  Med: 2.43 Max: 3.01
Current: 2.57
1.47
3.01
P/S 1.54
FMS's P/S is ranked lower than
58% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 1.49 vs. FMS: 1.54 )
Ranked among companies with meaningful P/S only.
FMS' s 10-Year P/S Range
Min: 1.03  Med: 1.50 Max: 1.89
Current: 1.54
1.03
1.89
PFCF 22.21
FMS's PFCF is ranked lower than
54% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 21.20 vs. FMS: 22.21 )
Ranked among companies with meaningful PFCF only.
FMS' s 10-Year PFCF Range
Min: 13.96  Med: 22.84 Max: 54
Current: 22.21
13.96
54
POCF 12.79
FMS's POCF is ranked higher than
58% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 15.30 vs. FMS: 12.79 )
Ranked among companies with meaningful POCF only.
FMS' s 10-Year POCF Range
Min: 9.49  Med: 12.50 Max: 19.47
Current: 12.79
9.49
19.47
EV-to-EBIT 15.69
FMS's EV-to-EBIT is ranked higher than
59% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 19.98 vs. FMS: 15.69 )
Ranked among companies with meaningful EV-to-EBIT only.
FMS' s 10-Year EV-to-EBIT Range
Min: 7.4  Med: 12.50 Max: 17.6
Current: 15.69
7.4
17.6
PEG 3.38
FMS's PEG is ranked lower than
53% of the 66 Companies
in the Global Medical Care industry.

( Industry Median: 3.23 vs. FMS: 3.38 )
Ranked among companies with meaningful PEG only.
FMS' s 10-Year PEG Range
Min: 0.8  Med: 1.98 Max: 23.04
Current: 3.38
0.8
23.04
Shiller P/E 27.35
FMS's Shiller P/E is ranked higher than
53% of the 81 Companies
in the Global Medical Care industry.

( Industry Median: 31.33 vs. FMS: 27.35 )
Ranked among companies with meaningful Shiller P/E only.
FMS' s 10-Year Shiller P/E Range
Min: 17.38  Med: 24.48 Max: 34.27
Current: 27.35
17.38
34.27
Current Ratio 1.86
FMS's Current Ratio is ranked higher than
73% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. FMS: 1.86 )
Ranked among companies with meaningful Current Ratio only.
FMS' s 10-Year Current Ratio Range
Min: 0.8  Med: 1.40 Max: 1.93
Current: 1.86
0.8
1.93
Quick Ratio 1.53
FMS's Quick Ratio is ranked higher than
65% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. FMS: 1.53 )
Ranked among companies with meaningful Quick Ratio only.
FMS' s 10-Year Quick Ratio Range
Min: 0.7  Med: 1.15 Max: 1.61
Current: 1.53
0.7
1.61
Days Inventory 38.01
FMS's Days Inventory is ranked lower than
72% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 17.78 vs. FMS: 38.01 )
Ranked among companies with meaningful Days Inventory only.
FMS' s 10-Year Days Inventory Range
Min: 28.17  Med: 38.99 Max: 49.64
Current: 38.01
28.17
49.64
Days Sales Outstanding 81.14
FMS's Days Sales Outstanding is ranked lower than
84% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 46.60 vs. FMS: 81.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
FMS' s 10-Year Days Sales Outstanding Range
Min: 4.01  Med: 79.83 Max: 88.77
Current: 81.14
4.01
88.77

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.05
FMS's Dividend Yield is ranked lower than
72% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. FMS: 1.05 )
Ranked among companies with meaningful Dividend Yield only.
FMS' s 10-Year Dividend Yield Range
Min: 0.94  Med: 1.40 Max: 2.07
Current: 1.05
0.94
2.07
Dividend Payout 0.31
FMS's Dividend Payout is ranked higher than
68% of the 131 Companies
in the Global Medical Care industry.

( Industry Median: 0.43 vs. FMS: 0.31 )
Ranked among companies with meaningful Dividend Payout only.
FMS' s 10-Year Dividend Payout Range
Min: 0.91  Med: 1.11 Max: 1.36
Current: 0.31
0.91
1.36
Dividend growth (3y) 6.30
FMS's Dividend growth (3y) is ranked lower than
65% of the 63 Companies
in the Global Medical Care industry.

( Industry Median: 11.90 vs. FMS: 6.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
FMS' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 8
Current: 6.3
0
8
Yield on cost (5-Year) 1.52
FMS's Yield on cost (5-Year) is ranked lower than
62% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 1.91 vs. FMS: 1.52 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
FMS' s 10-Year Yield on cost (5-Year) Range
Min: 1.37  Med: 2.05 Max: 3.03
Current: 1.52
1.37
3.03
Share Buyback Rate 0.20
FMS's Share Buyback Rate is ranked higher than
84% of the 125 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. FMS: 0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
FMS' s 10-Year Share Buyback Rate Range
Min: 0.6  Med: -0.60 Max: -8.7
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.34
FMS's Price/Projected FCF is ranked higher than
57% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. FMS: 1.34 )
Ranked among companies with meaningful Price/Projected FCF only.
FMS' s 10-Year Price/Projected FCF Range
Min: 0.97  Med: 1.48 Max: 3.18
Current: 1.34
0.97
3.18
Price/DCF (Earnings Based) 1.83
FMS's Price/DCF (Earnings Based) is ranked lower than
65% of the 23 Companies
in the Global Medical Care industry.

( Industry Median: 1.43 vs. FMS: 1.83 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.13
FMS's Price/Median PS Value is ranked lower than
54% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. FMS: 1.13 )
Ranked among companies with meaningful Price/Median PS Value only.
FMS' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 0.98 Max: 1.77
Current: 1.13
0.22
1.77
Price/Peter Lynch Fair Value 4.47
FMS's Price/Peter Lynch Fair Value is ranked lower than
84% of the 50 Companies
in the Global Medical Care industry.

( Industry Median: 2.36 vs. FMS: 4.47 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
FMS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.9  Med: 1.98 Max: 4.69
Current: 4.47
0.9
4.69
Earnings Yield (Greenblatt) (%) 6.41
FMS's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. FMS: 6.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FMS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 5.7  Med: 8.00 Max: 13.5
Current: 6.41
5.7
13.5
Forward Rate of Return (Yacktman) (%) 9.28
FMS's Forward Rate of Return (Yacktman) (%) is ranked lower than
55% of the 101 Companies
in the Global Medical Care industry.

( Industry Median: 10.96 vs. FMS: 9.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
FMS' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -8.2  Med: 11.50 Max: 19.8
Current: 9.28
-8.2
19.8

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:0H9X.UK, FMCMF.USA, FMEN.Germany, FME3.Germany, FME.Switzerland, 0EH5.UK, FME N.Mexico, 0QJE.UK, FME.Germany, FMCQF.USA, FMEA.Germany,
Fresenius Medical Care AG & Co. KGaA was incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with different products. In addition, to providing dialysis treatments, includes pharmacy services and vascular access surgery services. It sells dialysis products to other dialysis service providers. It also develops and manufactures equipment, systems and disposable products, which it sells to customers in over 120 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company's clinics also provide services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. The Company provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates, including the U.S., at the federal, state and local levels.
» More Articles for FMS

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: FMS, MTB, LO, LEN Apr 05 2015 
Focus Graphite Announces Potential Lac Knife Project Financing Arrangements With Caterpillar Financi Jan 06 2015 
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 
Weekly 52-Week Highs Highlight: MMP, AZO, BEAM, FMS Jan 26 2014 
comment on FMS May 01 2013 
Better Know a Company: Fresenius Medical Care (FMS) Apr 23 2013 
Solid company. Opti Mar 26 2013 
39.64 Mar 18 2013 
comment on FMS Mar 17 2013 
Warren Buffett Becomes Largest Owner of DaVita Mar 04 2013 

More From Other Websites
Fresenius Medical Q2 Earnings Miss, Revenues Top Estimates - Analyst Blog Jul 31 2015
Fresenius Medical Care reports second quarter 2015 results and confirms guidance for full year 2015 Jul 29 2015
Fresenius Medical Care’s Patient Engagement May Have Saved Lives During Superstorm Sandy Jul 02 2015
Fresenius Medical Care Named to 2015 Forbes America’s Best Employers List Jun 10 2015
Fresenius Medical Care Joins Health Care Transformation Task Force May 28 2015
Fresenius Medical Earnings Lag, Revenues Beat Expectations - Analyst Blog May 05 2015
FMC confirms outlook as quarterly profit in line Apr 29 2015
Fresenius Medical Care reports first quarter 2015 results and confirms guidance for full year 2015 Apr 29 2015
Fresenius Medical Care Releases 2015 Annual Medical Quality Report Apr 16 2015
Germany Was below Expectations: EWG down 0.07% and FEZ dipped 0.25% Apr 14 2015
Eurozone’s Slumber Weighs down Factory Orders in Germany Apr 11 2015
Renal Research Institute Fellow Receives International Society of Nephrology Award Mar 25 2015
Fresenius Medical: 52-Week High on Solid Q4, Bright View - Analyst Blog Mar 17 2015
Fresenius Medical Care Supports World Kidney Day by Raising Awareness of Kidney Disease and the Need... Mar 12 2015
Heritage Provider Network and Fresenius Medical Care Announce Physician Network Development and Care... Mar 12 2015
Overseas Companies With High Exposure in the US Mar 10 2015
Overseas Companies With High Exposure in the US Mar 10 2015
FRESENIUS MEDICAL CARE AG & CO. KGAA Financials Mar 06 2015
Fresenius Renal Therapies President to Receive National Kidney Foundation “Gift of Life”... Mar 06 2015
During National Kidney Month, Fresenius Medical Care Celebrates Progress in Helping Patients with... Mar 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK